Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial

BACKGROUND: Genital herpes simplex infection affects more than 500 million people worldwide. We have previously shown that COR-1, a therapeutic HSV-2 polynucleotide vaccine candidate, is safe and well tolerated in healthy subjects. OBJECTIVE: Here, we present a single center double-blind placebo-con...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandra, Janin, Woo, Wai-Ping, Dutton, Julie L., Xu, Yan, Li, Bo, Kinrade, Sally, Druce, Julian, Finlayson, Neil, Griffin, Paul, Laing, Kerry J., Koelle, David M., Frazer, Ian H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917347/
https://www.ncbi.nlm.nih.gov/pubmed/31846475
http://dx.doi.org/10.1371/journal.pone.0226320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917347/
https://www.ncbi.nlm.nih.gov/pubmed/31846475
http://dx.doi.org/10.1371/journal.pone.0226320

Ejemplares similares